1-(2-Methylpropyl)cyclopropane-1-carboxylic acid | 1346641-21-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(2-Methylpropyl)cyclopropane-1-carboxylic acid
• 英文别名: 2,2-dimethyl-ethyl-cyclopropanecarboxylic acid；2-methylpropyl-1-cyclopropanecarboxylic acid；1-isobutylcyclopropane-1-carboxylic acid
• CAS: 1346641-21-1
• 化学式: C₈H₁₄O₂
• mdl: MFCD21669761
• 分子量: 142.198
• InChiKey: GOABMQWDEIMBRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-Methylpropyl)cyclopropane-1-carboxylic acid 在 草酰氯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 12.0h， 生成 N-(4-cyano-2,3,5,6-tetrafluorophenyl)-1-isobutylcyclopropanecarboxamide
  参考文献：
  名称：

  Pd(II)-Catalyzed Enantioselective C–H Activation of Cyclopropanes

  摘要：

  Systematic ligand development has led to the identification of novel mono-N-protected amino acid ligands for Pd(II)-catalyzed enantioselective C-H activation of cyclopropanes. A diverse range of organoboron reagents can be used as coupling partners, and the reaction proceeds under mild conditions. These results provide a new retro-synthetic disconnection for the construction of enantioenriched cis-substituted cyclopropanecarboxylic acids.

  DOI：

  10.1021/ja207607s
• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-(2-Methylpropyl)cyclopropane-1-carboxylic acid
  参考文献：
  名称：

  Pd(II)-Catalyzed Enantioselective C–H Activation of Cyclopropanes

  摘要：

  Systematic ligand development has led to the identification of novel mono-N-protected amino acid ligands for Pd(II)-catalyzed enantioselective C-H activation of cyclopropanes. A diverse range of organoboron reagents can be used as coupling partners, and the reaction proceeds under mild conditions. These results provide a new retro-synthetic disconnection for the construction of enantioenriched cis-substituted cyclopropanecarboxylic acids.

  DOI：

  10.1021/ja207607s

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2018020242A1

  公开（公告）日：2018-02-01

  The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

  本发明涉及一种具有以下式（I）的化合物，该化合物可用作泛素特异性蛋白酶USP19活性的抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物进行治疗的方法。
• FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20170174672A1

  公开（公告）日：2017-06-22

  The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  这项发明涉及(S1P)调节剂的(杂)环化合物，包括这种化合物的药物组合物，以及在通过S1P受体介导的疾病或紊乱的治疗、缓解或预防中的用途。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070225285A1

  公开（公告）日：2007-09-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和包含这些化合物的药物组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这些FLAP调节剂的方法，单独或与其他化合物组合使用，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或症状。
• Pharmaceutical compounds
  申请人：ALMAC DISCOVERY LIMITED

  公开号：US11053213B2

  公开（公告）日：2021-07-06

  The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

  本发明涉及可用作泛素特异性蛋白酶 USP19 活性抑制剂的式 (I) 化合物。本发明还涉及包含这些化合物的药物组合物以及将这些化合物用于治疗的方法。
• PHARMACEUTICAL COMPOUNDS
  申请人：Almac Discovery Limited

  公开号：EP3490982A1

  公开（公告）日：2019-06-05